Autopsy report · NCT03216005

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System

“Project suspended by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 6 years before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Intervene, Inc.

Sponsor type

Industry

Conditions

Chronic Venous Insufficiency

Interventions

BlueLeaf System

Participants

14

Sites

5

Countries

Australia, Canada, New Zealand

Trials that died the same way

• Subjects With T2D or at Risk of T2D Cohort Follow-up
  “The sponsor has temporarily suspended study due to operational constraints.” (73% match in meaning)
• Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
  “Sponsor suspended development of the drug on September 3, 2008.” (69% match in meaning)
• Patient Perception of MultiPulse Therapy™ (MPT™)
  “Sponsor ceased operations” (69% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (67% match in meaning)
• A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
  “Sponsor stopped the study” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.